News headlines about Vanda Pharmaceuticals (NASDAQ:VNDA) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vanda Pharmaceuticals earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.6013547184204 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the news stories that may have impacted Accern’s scoring:

Shares of Vanda Pharmaceuticals (VNDA) opened at $15.50 on Tuesday. Vanda Pharmaceuticals has a 52 week low of $11.90 and a 52 week high of $18.99. The company has a market capitalization of $696.38, a price-to-earnings ratio of -48.44 and a beta of 1.23.

Several research analysts have recently issued reports on VNDA shares. Oppenheimer set a $26.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, October 29th. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a report on Wednesday, October 18th. Piper Jaffray Companies set a $26.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 19th. Seaport Global Securities started coverage on shares of Vanda Pharmaceuticals in a report on Friday, January 19th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $21.29.

In related news, CFO James Patrick Kelly sold 9,155 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.35, for a total value of $140,529.25. Following the completion of the sale, the chief financial officer now owns 144,721 shares of the company’s stock, valued at $2,221,467.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Gunther Birznieks sold 8,568 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.26, for a total value of $130,747.68. Following the completion of the sale, the senior vice president now directly owns 118,366 shares of the company’s stock, valued at approximately $1,806,265.16. The disclosure for this sale can be found here. Insiders sold 209,483 shares of company stock valued at $3,205,205 in the last ninety days. 7.60% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This story was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/vanda-pharmaceuticals-vnda-receives-daily-media-sentiment-score-of-0-11/1847735.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Insider Buying and Selling by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.